Topotecan for the treatment of small-cell lung cancer.
Lung cancer is the most prevalent and yet the most preventable malignancy worldwide. Owing to the propensity of small-cell lung cancer to early relapse and its relative resistance to subsequent treatment there is a need to improve currently available therapies. Topotecan has provided an efficacious and tolerable therapeutic option for patients with recurrent small-cell lung cancer, and the oral formulation has also been shown to be beneficial, even in elderly patients of poor performance status. Herein we review the role of topotecan in the treatment of small-cell lung cancer.
Nicum
Shibani J
SJ
Royal Marsden Hospital, London, UK. Shibani.Nicum@rmh.nhs.uk
O'Brien
Mary E R
ME
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000556:secondary; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D019772:Topotecan / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D019772:Topotecan